The DEA’s Cannabis Reclassification: A Shift in Federal Drug Policy and Its Broader Implications
The U.S. Drug Enforcement Administration’s (DEA) recent proposal to reclassify “botanical cannabis” from Schedule I to Schedule III marks a pivotal shift in federal drug policy, one that reflects an evolving understanding of cannabis’s medical benefits and lower abuse potential. This historic move, catalyzed by recommendations from the Department of Health and Human Services (HHS) […]
